The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.

Positive safety and efficacy data from 4 clinical studies supported the CE marking.

The safety and efficacy of vibegron are supported by data from the phase 3 COURAGE and EMPOWUR trials.

A national survey found US hospitals expanded CAUTI prevention over 20 years, but use of key catheter-removal strategies remains variable.

Rezūm improved symptoms and quality of life at 1 year vs combination pharmacotherapy in sexually active men with BPO while preserving sexual function.

Sri Sivalingam, MD, discusses how suction-based technologies are improving stone clearance and raising expectations for ureteroscopic stone treatment.

Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.

Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.